Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y, Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 5, 2008, Pages 564-565

  Penson, David F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO;

ADULT; CANCER EPIDEMIOLOGY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INCIDENCE; MALE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RISK REDUCTION; SENSITIVITY ANALYSIS; SHORT SURVEY;

EID: 50649125820     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.07.028     Document Type: Short Survey

References (2)

1. Unger J.M., Thompson Jr. I.M., LeBlanc M., et al. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer 103 (2005) 1375
2. Zeliadt S.B., Etzioni R.D., Penson D.F., et al. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 118 (2005) 850